Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning versus bedtime nebulized rhDNase in cystic fibrosis
NL-OMON20146Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of dornase alfa in cystic fibrosis (CF) (2 arms), sponsored by Roche. Primary endpoint: MEF25. Started Sep 2004; status: active, not recruiting.
02
Drugs
dornase alfa
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON20146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20146.